IMMULITE/IMMULITE 1000 Systems, Third Generation PSA, Catalog Number/REF LK3PS1, SMN 10706293 (US Kit Catalog) Product Usage: For in vitro diagnostic use with the IMMULITE® and IMMULITE 1000 Analyzers for the quantitative measurement of prostate-specific antigen (PSA) in human serum, as an aid in the detection of prostate cancer when used in conjunction with digital rectal examination (DRE) in men aged 50 years or older. This assay is further indicated as an adjunctive test to aid in the management of prostate cancer patients.
Published February 8, 2017 · Recall initiated: December 21, 2016
Summary
FDA records medical device Class II recall Z-1120-2017, published February 8, 2017 and initiated December 21, 2016. Recalling firm: Siemens Healthcare Diagnostics, Inc.; Status: Terminated; Reported quantity: 1379 kits (190 kits in U.S.A and 1189 Kits internationally) in total; Lot: Lot Numbers: 1) D01196 - Expiration date 2016-12-31 2) D0120 - Expiration date 2017-03-31. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Negative bias results with the IMMULITE® /IMMULITE® 1000 Third Generation PSA (prostate-specific antigen) kit was confirmed for two lots (D0119 and D0120). The investigation by Siemens has confirmed that patient samples exhibit an average negative bias of approximately -22% with a range of -16% to -27% for samples recovering from 0.08 to 16.2 ng/mL.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Siemens Healthcare Diagnostics, Inc.
- Distributor
- Worldwide Distribution - US Nationwide and the countries of Denmark, Brazil, Croatia and Germany
- Lot
- Lot Numbers: 1) D01196 - Expiration date 2016-12-31 2) D0120 - Expiration date 2017-03-31
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAAtellica CH Revised C-Reactive Protein (RCRP); Siemens Material Number (SMN): 11537223;October 7, 2026
- FDABeckman Coulter, Emit 2000 Quinidine Assay REF: OSR4Q229 Contents: R1: 2 x 23 mL;R2 2x13 mLAugust 26, 2026
- FDASyva EMIT 2000 Quinidine Assay REF: 4Q019UL Contents: 1x28 mL, 1x14mLAugust 26, 2026
- FDASyva Emit tox Serum Tricyclic Antidepressant Calibrator/Controls SMN 10445390 Catalog No. 7C219ULAugust 12, 2026
- FDAMammomat Inspiration full, field digital,system,x-ray,mammographic Product Usage: The Mammomat InspirationFebruary 8, 2017
- FDAMedtronic Strata II / Strata NSC Valves (includes Burr Hole and Lumbar Peritoneal. All Catalog Numbers.February 8, 2017
Questions about this recall
Was IMMULITE/IMMULITE 1000 Systems, Third Generation PSA, Catalog Number/REF LK3PS1, SMN 10706293 (US Kit Catalog) Product Usage: For in vitro diagnostic use with the IMMULITE® and IMMULITE 1000 Analyzers for the quantitative measurement of prostate-specific antigen (PSA) in human serum, as an aid in the detection of prostate cancer when used in conjunction with digital rectal examination (DRE) in men aged 50 years or older. This assay is further indicated as an adjunctive test to aid in the management of prostate cancer patients. recalled?
Yes. FDA published recall Z-1120-2017 on February 8, 2017. Reported hazard: Negative bias results with the IMMULITE® /IMMULITE® 1000 Third Generation PSA (prostate-specific antigen) kit was confirmed for two lots (D0119 and D0120). The investigation by Siemens has confirmed that patient samples exhibit an average negative bias of approximately -22% with a range of -16% to -27% for samples recovering from 0.08 to 16.2 ng/mL.
What should I do if I have this product?
Voluntary: Firm initiated · Letter